Salud financiera de hoja de balance de Lansen Pharmaceutical Holdings

Salud financiera controles de criterios 5/6

Lansen Pharmaceutical Holdings tiene un patrimonio de accionistas total de $123.6M y una deuda total de $17.6M, lo que sitúa su ratio deuda-patrimonio en 14.2%. Sus activos y pasivos totales son $175.0M y $51.3M respectivamente. El BAIT de Lansen Pharmaceutical Holdings es de $12.4M, por lo que su ratio de cobertura de intereses es de -35.1. Tiene efectivo e inversiones a corto plazo que ascienden a $46.4M.

Información clave

14.2%

Ratio deuda-patrimonio

US$17.58m

Deuda

Ratio de cobertura de intereses	-35.1x
Efectivo	US$46.39m
Patrimonio	US$123.64m
Total pasivo	US$51.34m
Activos totales	US$174.98m

Actualizaciones recientes sobre salud financiera

Recent updates

Does Lansen Pharmaceutical Holdings (HKG:503) Have A Healthy Balance Sheet?

Sep 18

Is Lansen Pharmaceutical Holdings (HKG:503) Using Too Much Debt?

Mar 27

Lansen Pharmaceutical Holdings (HKG:503) Has A Rock Solid Balance Sheet

Sep 27

Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?

Dec 06

Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?

Sep 04

We're Not So Sure You Should Rely on Lansen Pharmaceutical Holdings's (HKG:503) Statutory Earnings

Dec 28

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($125.7M) de 503 superan a sus pasivos a corto plazo ($49.4M).

Pasivo a largo plazo: Los activos a corto plazo de 503 ($125.7M) superan a sus pasivos a largo plazo ($2.0M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: 503 tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de 503 ha pasado de 88.6% a 14.2% en los últimos 5 años.

Cobertura de la deuda: La deuda de 503 no está bien cubierta por el flujo de caja operativo (14.3%).

Cobertura de intereses: 503 gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.

Salud financiera de hoja de balance de Lansen Pharmaceutical Holdings

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Lansen Pharmaceutical Updates Withdrawal of Listing of Shares on Stock Exchange

Lansen Pharmaceutical Updates Withdrawal of Listing of Shares on Stock Exchange

Does Lansen Pharmaceutical Holdings (HKG:503) Have A Healthy Balance Sheet?

Is Lansen Pharmaceutical Holdings (HKG:503) Using Too Much Debt?

Lansen Pharmaceutical Holdings (HKG:503) Has A Rock Solid Balance Sheet

Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?

Recent updates

Lansen Pharmaceutical Updates Withdrawal of Listing of Shares on Stock Exchange

Lansen Pharmaceutical Updates Withdrawal of Listing of Shares on Stock Exchange

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 27%

Investor sentiment improves as stock rises 20%

Does Lansen Pharmaceutical Holdings (HKG:503) Have A Healthy Balance Sheet?

First half 2023 earnings released: EPS: US$0.013 (vs US$0.017 in 1H 2022)

New major risk - Revenue and earnings growth

Lansen Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 24, 2023

Investor sentiment improves as stock rises 18%

Is Lansen Pharmaceutical Holdings (HKG:503) Using Too Much Debt?

Full year 2022 earnings released

Lansen Pharmaceutical Holdings Limited Provides Earnings Guidance for the Twelve Months Ended 31 December 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Lansen Pharmaceutical Holdings (HKG:503) Has A Rock Solid Balance Sheet

Lansen Pharmaceutical Holdings Limited Appoints Zhu Xun as Independent Non-Executive Director and Member of the Remuneration Committee

First half 2022 earnings released: EPS: US$0.017 (vs US$0.004 in 1H 2021)

Lansen Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 31, 2022

Lansen Pharmaceutical Holdings Limited Approves to Elect Chan Ching Har, Eliza as an Independent Non-Executive Director

Investor sentiment improved over the past week

Lansen Pharmaceutical Holdings Limited has completed a Follow-on Equity Offering in the amount of SGD 59.424 million.

Full year 2021 earnings released: EPS: US$0.002 (vs US$0.22 in FY 2020)

Lansen Pharmaceutical Holdings Limited, Annual General Meeting, Jun 23, 2022

Lansen Pharmaceutical Holdings Limited Announces Resignation of Stephen Burnau Hunt as Non-Executive Director and Member of the Remuneration Committee

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Lansen Pharmaceutical Holdings Limited to Report Fiscal Year 2021 Results on Feb 28, 2022

Lansen Pharmaceutical Holdings Limited Announces Executive Changes

Lansen Pharmaceutical Holdings Limited Provides Earnings Guidance for the Year Ended December 31, 2021

Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?

First half 2021 earnings released: EPS US$0.004 (vs US$0.24 in 1H 2020)

Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?

Lansen Pharmaceutical Holdings Limited Declares a Special Dividend, Payable on 28 September 2021

Investor sentiment improved over the past week

Chairman recently bought HK$313k worth of stock

Full year 2020 earnings released: EPS US$0.22 (vs US$0.045 in FY 2019)

Lansen Pharmaceutical Holdings Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

New 90-day high: HK$1.92

We're Not So Sure You Should Rely on Lansen Pharmaceutical Holdings's (HKG:503) Statutory Earnings

Chairman recently bought HK$1.4m worth of stock

New 90-day high: HK$0.87

New 90-day high - HK$0.81

Lansen Pharmaceutical Holdings Limited to Report First Half, 2020 Results on Aug 27, 2020

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera